ID
13750
Description
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure; ODM derived from: https://clinicaltrials.gov/show/NCT01133886
Lien
https://clinicaltrials.gov/show/NCT01133886
Mots-clés
Versions (1)
- 02/03/2016 02/03/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
2 mars 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myeloid Leukemia NCT01133886
Eligibility Acute Myeloid Leukemia NCT01133886
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
1. nursing and pregnant females.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Description
2. females of childbearing potential and males not willing to practice an effective method of contraception whilst receiving decitabine and for 2 months after the last infusion.
Type de données
boolean
Alias
- UMLS CUI [1]
- C3831118
- UMLS CUI [2]
- C0700589
Description
3. patients with previous malignancy or concurrent malignancy.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
4. uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure and unstable angina pectoris.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0009488
Description
5. ongoing oral corticosteroids are not permitted. however, use of corticosteroids (topical and inhaled) is permitted and prophylactic steroids are allowed for transfusion reactions.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0001617
Description
6. patients who have received any investigational agent within the 30 days preceding the first dose of study drug.
Type de données
boolean
Alias
- UMLS CUI [1]
- C1875319
Description
7. patients who have received prior intensive combination chemotherapy or high-dose cytarabine (>/= 1g/m*2 per dose). (prior biologic therapies, targeted therapies and single agent chemotherapy are allowed).
Type de données
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0010711
Description
8. patients who have an active viral or bacterial infection. note: no patient is allowed to enter the study unless infections have been fully treated and the patient has remained afebrile for 7 days without antibiotics.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0009450
Description
9. patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0002880
- UMLS CUI [2]
- C0272286
Description
10. patients who have previously been treated with decitabine.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0049065
- UMLS CUI [1,2]
- C1514463
Description
11. patients who have known positive serology for hiv.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0019682
Description
12. patients with a condition that may be unable to comply with the treatment and monitoring requirements of the study.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Similar models
Eligibility Acute Myeloid Leukemia NCT01133886
- StudyEvent: Eligibility
C0023480 (UMLS CUI [2])
C0023467 (UMLS CUI [3])
C1982687 (UMLS CUI [4])
C0438286 (UMLS CUI [1,2])
C0201899 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
C0010711 (UMLS CUI [2])
C0272286 (UMLS CUI [2])
C1514463 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])